Page 1

EX - 99.1 2 eypt - ex991_6.htm EX - 99.1 EYEPOINT PHARMACEUTICALS Exhibit 99.1 EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate Developments - EYP - 1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January ; study remains on track for initial data in Q4 2021 ; -Completed $ 115.1 million follow - on financing in February 2021 ; -Net product revenues of $ 6.8 million versus $ 4.7 million in Q1 2020 , a 45 % increase ; -Asia partner Ocumension Therapeutics new drug application ( NDA ) accepted for review by the National Medical Products Administration ( NMPA ) for OT - 401 ( YUTIQâ ) - Management to host a conference call and webcast today at 8:30 AM ET – WATERTOWN , Mass . , May 5 , 2021 ( GLOBE NEWSWIRE ) -- EyePoint Pharmaceuticals , Inc. ( NASDAQ : EYPT ) , a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders , today announced financial results for the first quarter ended March 31 , 2021 and highlighted recent corporate developments . " This quarter was a productive one for EyePoint , as we continued to execute on our plan to advance our exciting pipeline of ocular products that have the potential to disrupt current treatment paradigms , ” said Nancy Lurker , Chief Executive Officer of EyePoint Pharmaceuticals . " We are very pleased to have initiated the Phase 1 DAVIO clinical trial in patients with wet - age macular degeneration ( wet AMD ) in January and this trial remains on track for interim data in the fourth quarter of this year . " Ms. Lurker continued , “ We were also very pleased to complete a $ 115.1 million follow - on financing during the first quarter positioning us to advance and expand our pipeline efficiently and purposefully , including plans to expand EYP - 1901 into clinical trials in diabetic retinopathy ( DR ) and retinal vein occlusion ( RVO ) . “ On the commercial front , we had a solid first quarter , which historically is weak due to co - pay and coinsurance annual resets , beating 4Q2020 and 45 % above 1Q2020 net product revenues . We also are very pleased with our DEXYCU® co - promotion partnership with ImprimisRx and the product demand it is now generating . Corporate Update In February 2021 , the Company completed an upsized underwritten public offering with gross proceeds of $ 115.1 million .